However, treatments like bevacizumab, a humanized monoclonal antibody targeting VEGF, and small molecule inhibitors like sorafenib and sunitinib, which target VEGFR, have shown limited efficacy in cancers such as HCC. This evidence concerns the gene VEGFA and cancer.